EMBC Embecta Corp.

Embecta Corp.

Medical/Dental Instruments

Health Care

Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety devices, as well as digital applications to assist people with managing their diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is based in Parsippany, New Jersey. Embecta Corp.(NasdaqGS:EMBC) operates independently of Becton, Dickinson and Company as of April 1, 2022.

IPO Year:

Exchange: NASDAQ

Website: https://www.embecta.com

Recent Analyst Ratings for Embecta Corp.

Date	Price Target	Rating	Analyst
4/10/2025	$15.00	Neutral	Mizuho
12/2/2024	$13.00 → $20.00	Underweight → Equal-Weight	Morgan Stanley
11/27/2024	$26.00	Neutral → Buy	BTIG Research
10/20/2023		Peer Perform	Wolfe Research
1/6/2023	$28.00	Equal-Weight → Underweight	Morgan Stanley
9/8/2022		Neutral	BTIG Research
8/1/2022	$33.00	Equal-Weight	Morgan Stanley
6/21/2022	$25.00	Underperform	BofA Securities

See more ratings

Embecta Corp.

Recent Analyst Ratings for Embecta Corp.

Embecta Corp. Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Director Melcher David F bought $105,995 worth of shares (10,000 units at $10.60), increasing direct ownership by 13% to 86,681 units (SEC Form 4)

SVP and CFO Elguicze Jacob covered exercise/tax liability with 4,948 shares, decreasing direct ownership by 3% to 168,599 units (SEC Form 4)

SVP, Global Manuf./Sup. Chain Curtis Shaun covered exercise/tax liability with 3,249 shares, decreasing direct ownership by 5% to 59,061 units (SEC Form 4)

SVP, GC, Head Corp. Dev., Secy Mann Jeffrey Z covered exercise/tax liability with 5,285 shares, decreasing direct ownership by 4% to 139,439 units (SEC Form 4)

President and CEO Kurdikar Devdatt covered exercise/tax liability with 39,592 shares, decreasing direct ownership by 7% to 499,582 units (SEC Form 4)

Director Melcher David F bought $177,646 worth of shares (13,000 units at $13.67), increasing direct ownership by 20% to 76,681 units (SEC Form 4)

Director Morris Milton Mayo was granted 13,839 shares and sold $50,783 worth of shares (3,100 units at $16.38), increasing direct ownership by 42% to 36,133 units (SEC Form 4)

Director Albritton David was granted 13,839 shares, increasing direct ownership by 53% to 39,743 units (SEC Form 4)

Director Anderson Carrie L was granted 13,839 shares, increasing direct ownership by 53% to 39,743 units (SEC Form 4)

Director Prange Karen was granted 13,839 shares, increasing direct ownership by 53% to 39,743 units (SEC Form 4)

Embecta Corp. SEC Filings

SEC Form SD filed by Embecta Corp.

Embecta Corp. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

Amendment: SEC Form SCHEDULE 13G/A filed by Embecta Corp.

Amendment: SEC Form SCHEDULE 13G/A filed by Embecta Corp.

SEC Form 10-Q filed by Embecta Corp.

Embecta Corp. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

Embecta Corp. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

SEC Form 144 filed by Embecta Corp.

SEC Form 10-Q filed by Embecta Corp.

Embecta Corp. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

Embecta Corp. Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Mizuho initiated coverage on Embecta Corp. with a new price target

Embecta Corp. upgraded by Morgan Stanley with a new price target

Embecta Corp. upgraded by BTIG Research with a new price target

Wolfe Research initiated coverage on Embecta Corp.

Embecta Corp. downgraded by Morgan Stanley with a new price target

BTIG Research initiated coverage on Embecta Corp.

Morgan Stanley initiated coverage on Embecta Corp. with a new price target

BofA Securities initiated coverage on Embecta Corp. with a new price target